Kyndryl (NYSE:KD) Q3 2026 Earnings call February 09, 2026 08:30 AM ET Speaker3Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Lori Chaitman, Global Head of Investor Relations. Please go ahead.Speaker7Good morning, everyone, and welcome to Kyndryl's earnings call for the third fiscal quarter ended December 31, 2025. Before we begin, I'd like to remind you that our remarks today include forward-looking statements. These sta ...

Financial Data and Key Metrics Changes - The cash position at December 31 was $131.7 million with no debt, and the company utilized $7.1 million in operating activities during the quarter, indicating a cash runway of more than three years at the current utilization rate [9][10] - Research and development expenses decreased to $4.7 million from $10.4 million in the same quarter last year, while general and administrative expenses fell to $2.1 million from $3.1 million [9][10] - The net loss for the quarter was reported at $5.7 million, or $0.06 per share [10] Business Line Data and Key Metrics Changes - The decrease in operating expenses was primarily due to the completion of a large manufacturing campaign for blarcamesine and a reduction in clinical trial activities following the completion of the Anavex 3-71 phase II study in schizophrenia [10] Market Data and Key Metrics Changes - The company is participating in the ACCESS-AD initiative, which aims to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease across Europe [3][4] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, particularly the lead candidate oral blarcamesine for early Alzheimer's disease, and is working with regulatory agencies in Europe and the U.S. to develop this treatment [3][4] - Anavex plans to provide updates on regulatory and clinical trial developments for blarcamesine in other indications, including Parkinson's disease and fragile X syndrome [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of blarcamesine to improve the lives of patients with neurological disorders and emphasized the importance of regulatory feedback in advancing their development plans [3][4] - The company acknowledged the challenges faced in the regulatory process but remains committed to addressing the feedback received from the FDA and EMA [4][24] Other Important Information - The company is preparing for a confirmatory study as part of the conditional marketing authorization process, which will involve real-world cohorts of paying patients [44] - Anavex is also planning to present new scientific findings at upcoming conferences, which may further support its clinical claims [5][7] Q&A Session Summary Question: Can you provide additional information regarding the rapporteur and co-rapporteur for the re-examination of the CHMP opinion on blarcamesine? - The rapporteurs will be selected from the 27 EU countries [15] Question: What is the timeline for the re-examination process? - The re-examination process is expected to last for the first half of the year, involving a 60 + 60-day period for responses and reviews [16] Question: When do you anticipate filing a formal NDA submission with the FDA? - The company plans to advance this once closer to the submission date, following productive discussions with the FDA [17] Question: What additional information will be included in the resubmission to the EMA? - The resubmission will include data from the AD-004 study, A-Clear study population, and correlations of clinical efficacy with brain atrophy reduction [24] Question: Are there any ongoing trials currently? - The only ongoing trials are compassionate use programs for Rett Syndrome and Alzheimer's Disease, with plans for studies in Parkinson's Disease and Fragile X Syndrome [28] Question: Can you clarify the company's stance on the CHMP rejection regarding SIGMAR1 wild type patients? - The company believes the rejection may have misinterpreted the trial data, as significant effects were observed in the SIGMAR1 wild type population [38] Question: Will the company run a confirmatory phase 4 trial if approved under CMA? - Yes, a confirmatory study will be conducted as per regulatory guidelines [46] Question: How will blarcamesine be involved in the ACCESS-AD program? - Blarcamesine will be part of a placebo-controlled trial aimed at evaluating its efficacy in early Alzheimer's patients [48]

Financial Data and Key Metrics Changes - The company reported an organic net sales decline of 7% year-over-year, driven by lower sales in both North America and international segments [15] - Adjusted gross margin decreased to 19.5%, a drop of approximately 340 basis points year-over-year, primarily due to cost inflation and lower volume mix [15][16] - Adjusted EBITDA was $24 million, down from $38 million a year ago, reflecting lower gross margins [17][18] Business Line Data and Key Metrics Changes - In North America, organic net sales declined 10% year-over-year, primarily due to lower volume in snacks and baby formula, with adjusted gross margin at 20.8%, a decrease of 440 basis points [18][19] - The international segment saw a 3% decline in organic net sales, with adjusted gross margin at 18.1%, a 200 basis point decrease [19][20] - Snacks organic net sales were down 20% year-over-year, while the baby and kids segment saw a 14% decline [20] Market Data and Key Metrics Changes - North American snacks represented 22% of the company's net sales in fiscal 2025 and 38% of the North America segment's net sales, with negligible EBITDA contribution over the last 12 months [8][12] - The core categories in North America, including tea, yogurt, and baby foods, showed stability and growth potential despite challenges in other areas [12][18] Company Strategy and Development Direction - The company is executing a strategic review aimed at simplifying its portfolio, enhancing financial flexibility, and maximizing shareholder value [5][9] - A definitive agreement was reached to sell the North American snacks business for $115 million, with proceeds intended to reduce debt and strengthen the financial position [6][7] - The focus will shift to three flagship categories: tea, yogurt, and baby and kids, while continuing to develop the meal prep platform [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the turnaround strategy, highlighting improvements in operational execution and cash flow [12][14] - The company anticipates stronger top and bottom-line performance in the second half of the year, driven by ongoing initiatives and innovation [27][29] - Management acknowledged near-term pressures but emphasized the importance of strategic actions to drive sustainable growth [12][14] Other Important Information - Free cash flow in the second quarter was $30 million, an increase of 22% compared to the previous year [22] - The company has reduced net debt by $32 million, bringing total net debt to $637 million [23][24] - The strategic review includes plans for further asset sales and operational improvements to enhance financial flexibility [25] Q&A Session Summary Question: Details on the decision to divest the snacks portfolio - Management explained that the decision was part of a strategy to simplify the portfolio and focus on categories where the company has strengths, noting that snacks had become financially challenged [34][35] Question: Reallocation of innovations post-divestiture - Management confirmed plans to mitigate stranded costs of $20 million-$25 million and emphasized that freed resources would support innovation in remaining categories [41][42] Question: Cash generation from the snacks business - Management indicated that the snacks business was not a significant cash generator, and the divestiture would improve overall cash generation capabilities [45] Question: Future growth in the baby and kids business - Management expressed confidence in returning to growth in the baby and kids segment, particularly after cycling past challenges and launching new products [84][85]

Dynatrace (NYSE:DT) Q3 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAndrew Sherman - Directot and Enterprise SoftwareJim Benson - CFOKoji Ikeda - Director in Enterprise Software Equity ResearchNoelle Faris - VP of Investor RelationsRick McConnell - CEOConference Call ParticipantsBrad Reback - Managing Director and Equity Research AnalystBrent Thill - Tech Sector Leader and Software AnalystDeShaun Fontenot - Software Equity Research AnalystEric Heath - VP and Equity Research AnalystGr ...

Dynatrace (NYSE:DT) Q3 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAndrew Sherman - Directot and Enterprise SoftwareJim Benson - CFOKoji Ikeda - Director in Enterprise Software Equity ResearchNoelle Faris - VP of Investor RelationsRick McConnell - CEOConference Call ParticipantsBrad Reback - Managing Director and Equity Research AnalystBrent Thill - Tech Sector Leader and Software AnalystEric Heath - VP and Equity Research AnalystGray Powell - Managing Director and Security and Infr ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $5.3 billion, reflecting a 0.4% increase year-on-year, with New BD growing by 2.5% [5][18] - Adjusted gross margin was 53.4%, down 140 basis points from the prior year, primarily due to tariffs [20] - Adjusted EPS was $2.91, a decrease of 15.2% year-on-year, mainly impacted by tariffs [21] - Free cash flow for the quarter was $548 million, with a conversion rate of 66%, up from 59% in the prior year [22] Business Line Data and Key Metrics Changes - Medical Essentials experienced expected order timing dynamics and volume-based procurement in China, partially offset by share gains in the US [18] - Connected Care delivered mid-single-digit growth, led by high single-digit growth in APM [18] - Biopharma Systems grew low single digits, with double-digit growth in biologics, particularly GLP-1s, offset by lower vaccine demand [19] - Interventional and surgery segments both delivered solid mid-single-digit growth, with strong performance in Advanced Tissue Regeneration [19] Market Data and Key Metrics Changes - The US market showed solid growth in the BD Vacutainer portfolio, while challenges persisted in China due to market dynamics [18] - Alaris performance was slightly ahead of expectations despite a revenue decline due to tough comparisons to the prior year [19] - The Life Sciences segment declined due to US point-of-care headwinds and market dynamics in China [20] Company Strategy and Development Direction - The company is focused on a balanced capital allocation strategy, prioritizing share repurchases and tuck-in M&A in high-growth markets [8][9] - Key trends shaping the future of healthcare include the rise of smart devices, the shift towards lower-cost care settings, and the growth in chronic disease technologies [9][10] - The company aims to enhance its commercial capabilities and operational excellence through its "Excellence Unleashed" strategy, focusing on competing, innovating, and delivering [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, with core growth drivers remaining intact [27] - The company anticipates low single-digit revenue growth for New BD in fiscal 2026, with a positive currency impact expected [23] - Management acknowledged known headwinds in 10% of the portfolio but emphasized strong fundamentals in the remaining 90% [33] Other Important Information - The company is set to close a significant transaction with Waters, receiving a $4 billion cash distribution, with plans to allocate $2 billion for share repurchases and $2 billion for debt paydown [8][24] - The company has reduced its manufacturing network by nearly half, enhancing operational efficiency and cost management [16][56] Q&A Session Summary Question: Guidance for Q2 revenue and EPS - Management indicated that Q2 guidance reflects modest timing benefits and that core growth drivers remain intact, with no ramp expected from Q1 to Q2 [27][28] Question: Structural changes affecting mid-single-digit growth - Management confirmed confidence in the portfolio, noting strong performance in high-growth areas despite known headwinds [33] Question: Impact of Alaris and vaccines in China - Management expects Alaris to step up in 2027, with vaccines anticipated to have a smaller revenue impact moving forward [40][42] Question: M&A opportunities under New BD strategy - The company remains focused on tuck-in M&A that is accretive to revenue and EPS, with a robust pipeline in high-growth sectors [78][80] Question: Pricing environment and potential for price premiums - Management noted a stable pricing environment with slight positive pricing expected outside of China, anticipating improvements as VBP dynamics lessen [91]

Financial Data and Key Metrics Changes - In Q4 2025, NOI increased by 16% sequentially and almost 60% year-over-year, driven by acquisitions and organic growth [12] - Same-property NOI grew by 3.3% for the full year and 1.5% for Q4, despite a 50 basis point headwind from uncollectible revenue [14] - The company is forecasting FFO guidance for 2026 in the range of $1.17 to $1.21 per share, representing a 12% year-over-year growth [15][16] Business Line Data and Key Metrics Changes - The company signed over 400,000 sq ft of new leases and renewals in 2025, with new lease spreads averaging 20% and renewal spreads just under 10% [6] - The lease rate remained unchanged at 96.7%, with occupancy up 20 basis points [13] Market Data and Key Metrics Changes - The total U.S. market for convenience retail assets is 950 million sq ft, significantly larger than the company's current portfolio of almost 5 million sq ft [7] - The company has built a significant network of relationships with sellers and brokers, with 27% of acquisitions being direct and off-market [8] Company Strategy and Development Direction - The company focuses on acquiring top-tier convenience retail assets, emphasizing capital efficiency and a first-mover advantage in the sector [5] - The strategy includes investing in simple, flexible buildings that align with consumer behavior, catering to daily errands rather than destination shopping [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth opportunities in the convenience sector, citing a significant addressable investment market and a strong team to support growth [11] - The company expects to generate double-digit cash flow growth for several years, driven by capital efficiency and reinvestment of retained cash flow [11] Other Important Information - The company ended the year with a leverage ratio of less than 20%, providing substantial liquidity for future acquisitions [19] - The company has a unique capital structure aligned with its business plan, having raised $600 million in debt capital since formation [18] Q&A Session Summary Question: Can you talk about the acquisition pipeline and cap rates? - Management indicated that cap rates have remained just north of 6%, with a wide range depending on various factors [24] - The company has visibility on about half of the $700 million acquisition pipeline for 2026 [25] Question: Can you discuss same-store NOI and leasing spreads? - Management noted that leasing spreads are expected to return to low 20s, and same-property NOI guidance for 2026 is a wide range of 2%-4% [28][30] Question: Are there any operating synergies from having multiple properties in single markets? - Management acknowledged some operational synergies but emphasized that the high recovery rate of the asset class limits their impact on same-store NOI [36] Question: What is the thought process on incremental equity issuance versus building out the debt ladder? - Management highlighted a broad range of options for funding, including equity issuance and private placement, while maintaining a strong liquidity position [52] Question: Are there any planned dispositions for 2026? - Management confirmed that there are no planned dispositions, as the business model focuses on long-term ownership of acquired assets [63][65]

Aeries Technology (NasdaqCM:AERT) Q3 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAjay Khare - CEODaniel Webb - CFOOperatorToday, and welcome to Aeries Technology third quarter and fiscal year 2026 earnings call. Joining us today on the call are Aeries Chief Executive Officer Ajay Khare and Chief Financial Officer Daniel Webb. The call will review the results for the quarter ended December 31st, 2025, and outline strategic priorities that are shaping the next stage of our growth. Bef ...

The Hain Celestial Group (NasdaqGS:HAIN) Q2 2026 Earnings call February 09, 2026 08:00 AM ET Company ParticipantsAlexis Tessier - Head of Investor RelationsAlison Lewis - President and CEOAnthony Vendetti - Executive Managing Director of ResearchKaumil Gajrawala - Managing DirectorLee Boyce - CFOConference Call ParticipantsAndrew Lazar - Managing Director and Senior Equity Research AnalystJim Salera - Equity Research AnalystJohn Baumgartner - Managing Director and Senior Equity Research AnalystJon Andersen ...

Financial Data and Key Metrics Changes - The company reported a solid start to fiscal year 2026, with results modestly ahead of expectations, reflecting progress on its strategic focus areas [8][10] - Organic net sales decreased by 50 basis points, with North America showing strength that offset expected softness in international markets [10][22] - Adjusted EPS was reported at a loss of $0.16, compared to a loss of $0.10 in the prior quarter, while adjusted EBITDA was $25 million, down from $30.9 million in the prior year [27][28] Business Line Data and Key Metrics Changes - Organic net sales in North America grew just under 1%, driven by strong sun care performance, while Wet Shave organic net sales declined approximately 4% [22][24] - Sun and skincare organic net sales increased approximately 8%, with sun care growing nearly 20% in North America [24][25] - Grooming organic net sales growth was approximately 7%, led by significant growth in Cremo and Bulldog [24] Market Data and Key Metrics Changes - Over 70% of international markets either grew or held market share, with notable gains in Australia, Europe, Canada, and China [11][12] - In the U.S., market share pressure was modest, particularly in core Wet Shave, while men's grooming showed relative strength [10][11] - International Wet Shave organic net sales declined less than 1%, with volume declines partly offset by price gains [22] Company Strategy and Development Direction - The divestiture of the feminine care business is seen as a pivotal step in the company's transformation, allowing a sharper focus on core categories: shave, sun, skincare, and grooming [9][10] - The company aims to drive sustainable growth and stronger margins by reallocating capital and resources towards its core businesses [9][10] - The strategy includes a focus on international growth, innovation, productivity, and U.S. commercial transformation [12][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to organic net sales growth, driven by mid-single-digit growth in international markets and a more stable performance in North America [19][20] - The company anticipates gross margin expansion supported by productivity gains, despite inflationary pressures [20][21] - Management highlighted the importance of disciplined capital allocation and the use of proceeds from the FemCare sale for debt reduction [35][36] Other Important Information - The company declared a quarterly dividend of $0.15 per share, returning approximately $7 million to shareholders [28] - Adjusted free cash flow is expected to be in the range of $80 million to $110 million for the year, driven by working capital discipline [35] Q&A Session Summary Question: Thoughts on portfolio construction post-FemCare divestiture - Management emphasized the strategic move to divest the FemCare business, which was growth dilutive and capital intensive, allowing for a sharper focus on core categories [39][40] Question: Expectations for fiscal Q2 organic sales - Management expects organic net sales to be down about 3% in Q2, primarily due to shipment timing and phasing impacts [50][51] Question: Implications for FemCare dilution into fiscal 2027 - Management indicated that while there will be stranded costs to address, the company is committed to right-sizing its overhead structure and expects a stronger portfolio moving forward [53][56] Question: Promotional levels in North America for Shave - Management acknowledged that promotional intensity remains high, particularly in women's shaving, but expressed confidence in improved trends as new distribution and innovation are implemented [82]